1-4 of 4
Authors: Marie Bex
Save search
Sort by
Journal Article

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile Open Access

PDF
Richard J Auchus and others
Journal of the Endocrine Society, Volume 6, Issue Supplement_1, November-December 2022, Pages A525–A526, https://doi.org/10.1210/jendso/bvac150.1094
Published: 01 November 2022
Journal Article

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study Open Access

PDF
Richard Feelders and others
Journal of the Endocrine Society, Volume 6, Issue Supplement_1, November-December 2022, Page A546, https://doi.org/10.1210/jendso/bvac150.1135
Published: 01 November 2022
Journal Article

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4) Open Access

PDF
Mônica Gadelha and others
Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021, Pages A516–A517, https://doi.org/10.1210/jendso/bvab048.1055
Published: 03 May 2021
Journal Article

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study Open Access

Mônica Gadelha and others
Journal of the Endocrine Society, Volume 3, Issue Supplement_1, April-May 2019, SAT-433, https://doi.org/10.1210/js.2019-SAT-433
Published: 30 April 2019